Meeting Report

Current and Future Directions for PARP Inhibition

Presented by Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD

From Mayo Clinic, Rochester, Minnesota

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2020;11(3):297–300 | https://doi.org/10.6004/jadpro.2020.11.3.16 | © 2020 Harborside™


  

ABSTRACT

Megan Grudem, APRN, CNP, and Andrea Wahner Hendrickson, MD, reviewed the potential role of PARP inhibition in various malignancies, how to select patients who are appropriate candidates, and guidance on devising treatment plans that include PARP inhibitors for patients with ovarian or breast cancer based on genetic profiles, tolerability, dosing schedules, and other key factors. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.